Companion Diagnostic Device (CDx)
One of the opportunities that the ESN Cleer CDx strategy can provide is the most recently established drug class for treating pre-Heart Failure (Pre-HF) and Heart Failure with Preserved Ejection Fraction (HFpEF), by identifying patients who are otherwise undetected currently.
ESN Cleer’s biomarker panel enables testing solutions designed to be safe for easy-to-use, hygienic, in small form factor and provides rapid results. The test can leverage existing healthcare and biological testing infrastructure, ensuring streamlined integration for primary care in practice.
The testing application is being developed by ESN Cleer; a saliva-based pathology test. The test is anticipated to be an immunoassay laboratory test, coupled with ESN Cleer’s predictive model, Pre-HF and HFpEF patients can be identified. The results will enable precision drug intervention, by identifying responders for the drug through screening patients who are likely to get side effects and who are likely to respond well to the drug. A true precision medicine approach with subsequent periodic re-testing to facilitate treatment progression monitoring.